JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M209168200 on January 27, 2003

J. Biol. Chem., Vol. 278, Issue 14, 11962-11969, April 4, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/14/11962    most recent
M209168200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasegawa, Y.
Right arrow Articles by Fang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasegawa, Y.
Right arrow Articles by Fang, X.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor*

Yutaka HasegawaDagger , James R. Erickson§, Graham J. Goddard§||, Shuangxing YuDagger , Shuying LiuDagger , Kwai Wa ChengDagger , Astrid EderDagger , Koji Bandoh**, Junken Aoki**, Renata JaroszDagger Dagger , Andrew D. SchrierDagger Dagger , Kevin R. LynchDagger Dagger , Gordon B. MillsDagger , and Xianjun FangDagger §§

From the Dagger  M. D. Anderson Cancer Center, Houston, Texas 77030, § LXR Biotechnology, Richmond, California 94804, the ** University of Tokyo, Tokyo 113-0033, Japan, and the Dagger Dagger  Department of Pharmacology, University of Virginia Health System, Charlottesville, Virginia 22908

Lysophosphatidic acid (LPA) is a bioactive lysophospholipid mediator that acts through G protein-coupled receptors. Most cell lines in culture express one or more LPA receptors, making it difficult to assign a response to specific LPA receptors. Dissection of the signaling properties of LPA has been hampered by lack of LPA receptor subtype-specific agonists and antagonists. The present study characterizes an ester-linked thiophosphate derivative (1-oleoyl-2-O-methyl-rac-glycerophosphothionate, OMPT) of LPA. OMPT is a functional LPA analogue with potent mitogenic activity in fibroblasts. In contrast to LPA, OMPT does not couple to the pheromone response through the LPA1 receptor in yeast cells. OMPT induces intracellular calcium increases efficiently in LPA3 receptor-expressing Sf9 cells but poorly in LPA2 receptor-expressing cells. Guanosine 5'-O-(3-[35S]thio)triphosphate binding assays in mammalian cells showed that LPA exhibits agonistic activity on all three LPA receptor subtypes, whereas OMPT has a potent agonistic effect only on the LPA3 receptor. In transiently transfected HEK293 cells, OMPT stimulates mitogen-activated protein kinases through the LPA3 but not the LPA1 or LPA2 receptors. Furthermore, OMPT-induced intracellular calcium mobilization in mammalian cells is efficiently inhibited by the LPA1/LPA3 receptor-selective antagonist VPC12249. These results establish that OMPT is an LPA3-selective agonist. OMPT binding to the LPA3 receptor in mammalian cells is sufficient to elicit multiple responses, including activation of G proteins, calcium mobilization, and activation of mitogen-activated protein kinases. Thus OMPT offers a powerful probe for the dissection of LPA signaling events in complex mammalian systems.


* The work was supported by Atairgin Technologies Contract LS99-225RG, the Lynne Cohen Foundation Ovarian Cancer Research Grant 80095031 (to X. F.), and by National Institutes of Health Grants CA64602 (to G. B. M.), CA88994, and GM052722 (to K. R. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: AGY Therapeutics, South San Francisco, CA.

|| Present address: Genentech Inc., South San Francisco, CA.

§§ To whom correspondence should be addressed: M. D. Anderson Cancer Center, Dept. of Molecular Therapeutics, Box 317, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-745-1134; Fax: 713-745-1184; E-mail: Xianjunfang@mail.mdanderson.org.


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
M. M. Murph, J. Hurst-Kennedy, V. Newton, D. N. Brindley, and H. Radhakrishna
Lysophosphatidic Acid Decreases the Nuclear Localization and Cellular Abundance of the p53 Tumor Suppressor in A549 Lung Carcinoma Cells
Mol. Cancer Res., November 1, 2007; 5(11): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Anliker and J. Chun
Lysophospholipid G Protein-coupled Receptors
J. Biol. Chem., May 14, 2004; 279(20): 20555 - 20558.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Hama, J. Aoki, M. Fukaya, Y. Kishi, T. Sakai, R. Suzuki, H. Ohta, T. Yamori, M. Watanabe, J. Chun, et al.
Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and Non-neoplastic Cells through LPA1
J. Biol. Chem., April 23, 2004; 279(17): 17634 - 17639.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D.-S. Im
Discovery of new G protein-coupled receptors for lipid mediators
J. Lipid Res., March 1, 2004; 45(3): 410 - 418.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. D. Okusa, H. Ye, L. Huang, L. Sigismund, T. Macdonald, and K. R. Lynch
Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury
Am J Physiol Renal Physiol, September 1, 2003; 285(3): F565 - F574.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.